• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

    1.800 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Phio Pharmaceuticals Corp. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
    Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior... 
    Via Newsfile
    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
    Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing... 
    Via Newsfile
    Exposures Lead
    Top movers in Wednesday's session
    Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
    Via Chartmill
    Top movers analysis in the middle of the day on 2025-04-23: top gainers and losers in today's session.
    Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    The market is filled with gapping stocks in Wednesday's session.
    The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
    Via Chartmill
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Tuesday's after hours session: top gainers and losers
    Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
    Via Chartmill
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    The trading volume of these stocks is deviating from the norm in today's session.
    Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
    Via Chartmill
    Which stocks are moving on Wednesday?
    Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
    Via Chartmill
    Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled
    CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin... 
    Via Stocktwits
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    The market is filled with gapping stocks in Wednesday's session.
    In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
    Via Chartmill
    Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results
    Via Benzinga
    Exposures Fossil Fuels
    Top movers in Wednesday's pre-market session
    Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
    Via Chartmill
    Nasdaq Gains Over 100 Points; Delta Air Lines Posts Upbeat Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
    Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing... 
    Via Newsfile
    Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
    To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,... 
    Via Newsfile
    Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
    Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile... 
    Via Newsfile
    American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
    Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
    Via Newsfile
    Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
    Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
    Via Newsfile
    Exposures Product Safety
    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
    Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that... 
    Via Newsfile
    Exposures Lead
    Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
    Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
    Via Newsfile
    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
    Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
    Via Newsfile
    Exposures Lead
    Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
    Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics... 
    Via Newsfile
    Exposures Lead
    Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs... 
    Via Newsfile
    Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics... 
    Via Newsfile
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.